Lupin Limited has informed the Exchange about Investor Presentation on the Unaudited Financial Results for the quarter and nine months ended on December 31, 2025.
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Lupin posted strong Q3 FY26 results with net sales of INR 71,005 million, up 26% year-on-year. EBITDA jumped 62% to INR 22,095 million with margins expanding to 31.1% from 24.3% a year ago, driven by cost optimization and a better product mix. Net income rose 38% to INR 11,756 million (includes one-time exceptional items of INR 4,266 million). The US business recorded its highest-ever quarterly sales of $350 million (up 46% YoY), led by new launches including the Risperdal Consta generic and the pegfilgrastim biosimilar Armlupeg. India grew 6% YoY to INR 20,387 million, slightly hit by loss of exclusivity in the in-licensed portfolio. Management also shared multi-year targets: 100+ new product launches in the US with ~65% share from complex products by FY31, and ~70% chronic share in India by FY30, alongside 20 complex launches and 10 novel pipeline products by 2028.
Strong margin expansion, robust US momentum and a deleveraged balance sheet (Net Debt/Equity turned negative at -0.14x) are positive for shareholders. Clear multi-year targets around complex generics and biosimilars suggest management confidence, though India's slowing growth is a minor watchpoint.